Show Summary Details
Page of

JAG1 and NOTCH2 and the Alagille Syndrome 

JAG1 and NOTCH2 and the Alagille Syndrome
JAG1 and NOTCH2 and the Alagille Syndrome

Nancy B. Spinner

, Laura D. Leonard

, Alexandra M. Falsey

, and Ian D. Krantz

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 07 March 2021

Alagille Syndrome is a multisystem, autosomal dominant, developmental disorder with clinical manifestations in the hepatic, cardiac, ophthalmologic and skeletal systems, accompanied by characteristic facial features. The most common features include bile duct paucity and resultant cholestasis, peripheral pulmonic stenosis (with tetralogy of Fallot the most common intracardiac defect), posterior embryotoxon and butterfly vertebrae and expressivity of all systems is highly variable. A smaller percent of patients also have renal and vascular anomalies. The disorder is caused by mutation in 2 genes in the Notch Signaling Pathway, the cell surface ligand Jagged1 (JAG1) seen in a high percentage of patients (about 94%) and the Notch receptor NOTCH2 seen in a smaller percent (1-2%).

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.